Novacyt provides an R&D update on its initial molecular products pipeline

R&D Strategy Update PR ENGLISH Paris, France and Cambridge, UK – 5th September 2016 – Novacyt (ALTERNEXT: ALNOV), an international clinically focused diagnostics company, today provides a Research and Development (R&D) update following the completion of the acquisition of Primerdesign in May 2016. The integration of Primerdesign is progressing well, in line with the strategic

Visit Page

NOVACYT SHARE CAPITAL UPDATE

Novacyt_CP_Conversion OCA_31082016_ENG Paris, France and Cambridge, UK – 31st August 2016 – Novacyt (ALTERNEXT: ALNOV), an international clinically focused diagnostics company, today announces the conversion of 15 convertible bond units from tranches five and six of the flexible bond financing agreement concluded on 31st July, 2015 with YA II PN, Ltd (formerly YA Global Master

Visit Page

NOVACYT HALF YEAR 2016 REVENUES

Novacyt half-year 2016 revenue Continued strong growth in Novaprep® sales Strong growth from the acquisition of Primerdesign

Visit Page